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INTRODUCTION 
  
 
 
INTRODUCTION 
 
Abortion is universal, through history women have sought to 
terminate an unwanted pregnancy. Despite increased use of 
contraception, the need for abortion continues to be high. Prevention of 
unwanted pregnancy has been the top-priority concern with all health 
planning. A large number of abortions are performed worldwide. 
Approximately 1/3 to ½ of all at least one induced abortion performed 
under unsafe conditions. The safety and efficacy of the procedure used is 
therefore of global public health importance.  
 Approximately 35 million induced abortions that take place each 
year around the globe.  
 Despite the liberalization of abortion services since the early 
1970s, access to safe abortion services remains limited for the vast 
majority of Indian women, particularly in rural areas. In India incidence 
of induced abortions is 6.7 million annually. 
 According to government data, only about one million of these are 
performed legally. The remaining abortions are performed by medical 
and non-medical practitioners. Levels of unsafe abortion are very high in 
India. 
 
  
-1- 
  
The Reproductive and Child Health Programme launched in 1997 
and the National Population Policy, 2000 have also delineated a number 
of strategies to increase the access to safe abortion at the primary health 
care level. 
 Introduction of Medical Abortion in India is a landmark in 
women‟s health. Medical abortion is an approach to pregnancy 
termination which is non-invasive with minimal side-effects. 
 
Way to reduce unsafe abortion and maternal mortality by:  
 Providing basic training to providers of medical abortion on the 
regimen, correct prescription, side effects, post-abortion family 
planning, counselling and follow-up. 
 Educating women and men about their reproductive health rights 
and family planning in general. 
 Ensuring medical products meet the highest standards of quality 
and efficacy. 
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The mortality and morbidity rates are higher in second trimester 
termination of pregnancy than in the first trimester termination of 
pregnancy. There is a search for better, safer, quickest, cost effective, 
convenient and feasible method for termination in second trimester. 
 So in this study medical method of termination of second trimester 
pregnancy with two routes of administration of misoprostol is 
compared and taken for evaluation.  
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AIM OF THE STUDY 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
1. To compare the outcome of sublingual versus vaginal 
administration of misoprostol for induction of second trimester 
abortion. 
 
2. To evaluate the induction to abortion interval. 
 
 
3. To Study and evaluate the failure rate, complications and side 
effects. 
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REVIEW OF LITERATURE 
  
 
 
REVIEW OF LITERATURE 
 
 Our primary objective is to compare the efficacy and side effects of 
two different mode of administration of misoprostol (sublingual and 
vaginal) in second trimester termination of pregnancy. 
   
  Following are the studies conducted by various authors 
about the efficacy of misoprostol in second trimester termination of 
pregnancy. 
1)  BHATTACHARJEE N, SAHA SP, GHOSHROY SC, 
BHOWMIK S, BARUI G. A RANDOMIZED COMPARATIVE 
STUDY ON SUBLINGUAL VERSUS VAGINAL 
ADMINISTRATION OF MISOPROSTOL FOR TERMINATION 
OF PREGNANCY BETWEEN 13 TO 20 WEEKS. AUST N Z J 
OBSTET GYNAECOL 2008;48(2);165-71. 
 A randomized comparative trial where 300 women at 13-20 week 
gestation, requiring medical abortion, were randomly assigned to 
sublingual or vaginal route for misoprostol administration with a dose 
schedule of 400 µg three-hourly, up to a maximum five doses over 24 h. 
The same doses were repeated for another 24 h in non-responders. 
Primary outcome measure was complete abortion rate at 24 and 48h ; and 
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the secondary outcome measures were induction-abortion interval, failure 
rate, side effects and patients preference to the route. 
 No statistically significant differences in the complete abortion 
rates were observed at 24 h (64.03% vs 61.59%, P = 0.767) and at 48 h 
(79.14% vs 82.01% P = 0.651) when sublingual and vaginal groups were 
compared. Mean induction-abortion intervals in sublingual and vaginal 
groups were 14.1 hours and 14.5 hours, respectively (P = 0.066).  
Differences in the incidence of side-effects were also statistically 
insignificant when both groups were compared. 
 Both sublingual and vaginal administrations of misoprostol are 
equally effective in inducing medical abortion during second trimester 
but sublingual route was preferred by the patients. 
 
2) SHIVANI AGARWAR, PUSHPA BHATIA KASTURBA 
HOSPITAL, DELHI (2008) 
 They compared the efficacy, side effects and acceptability of 
sublingual and vaginal misoprostol for second trimester medical abortion. 
 Sixty women at 12-20 weeks of gestation attending tertiary care 
and teaching hospital, were randomized to receive either sublingual or 
vaginal misoprotol 400 µg every 4 hours in a prospective randomized 
controlled manner. The course of misoprostol was repeated only if the 
woman did not abort in the next 24 hours. 
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 There was no significant difference in the success rate at 24 hours 
(sublingual: 100%; vaginal: 93.4%). Five women in each group required 
D&C for completion. However, the success rate at 12 hours was 
significantly higher in the sublingual group (93%) compared with the 
vaginal group (38.4%). There was also a significant difference in the 
median induction-to-abortion interval. (Sublingual 7.5hrs & Vaginal 14.1 
hours) Further, more women in the sublingual group preferred the route 
to which they were assigned when compared with vaginal group. The 
incidence of fever was less in the sublingual group though vomiting was 
significant. 
 
3) HELENA VON HERTZEN1, GILDA PIAGGIO1, DANIEL 
WOJDYLA2, NGUYEN THI MY HUONG1 (AUGUST 2008) 
 To identify an effective misoprostol-only regimen for the 
termination of second trimester pregnancy, they compared sublingual and 
vaginal administration of multiple doses of misoprostol in a randomized, 
placebo-controlled equivalence trial. 
 Six hundred and eighty-one healthy pregnant women requesting 
medical abortion 13-20 weeks‟ gestation were randomly assigned. 400 µg 
of misoprostol administered either sublingually or vaginally every 3 h up 
to five doses, followed by sublingual administration of 400 µg 
misoprostol every 3 h up to five doses if abortion had not occurred at 24 h 
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after the start of treatment. Successful abortion within 48 h, was also 
considered as an outcome along with induction-to-abortion-interval, side 
effects and women‟s perceptions on these treatments. 
 At 24 h, the success (complete or incomplete abortion) rate was 
85.9% in the vaginal administration group and 79.8% in the sublingual 
group (difference: 6.1%, 95% CI: 0.5t o 11.8). Thus, equivalence could 
not be concluded overall. 
 Equivalence between vaginal and sublingual administration could 
not be demonstrated overall. Vaginal administration showed a higher 
effectiveness than sublingual administration in terminating second 
trimester pregnancies, but this result was mainly driven by nulliparous 
women. Fever was more prevalent with vaginal administration. 
Registered with international Standard Randomized Controlled Trial 
number. ISRCTN 72965671 
 
 
4) A.YASEMNIN KARAGEYIM KARSIDAG, ESRA E. 
BUYUKBAYRAK, BULENT KARS, RAMAZAN DANSUK, 
ORHAN UNAL, M.CEM TURAN. (2009) 
To compare the efficacy of vaginal versus sublingual misoprostal 
for second-trimester pregnancy termination, and to evaluate the effect on 
the blood flow of the uterine and umbilical arteries. Forty-nine patients 
were randomized to receive either 200 µg of vaginal misoprostol every 6 
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hours or 200 µg of misoprostol sublingually every 6 hours. Doppler 
velocimetry studies were assessed immediately before and 60 minutes 
after the administration of the first dose. 
 The  mean interval between induction and onset of active labor, 
induction and delivery, and the duration of oxytocin administration were 
significantly shorter in the sublingual misoprostol group. Both routes of 
administration increased the Doppler indices for the uterine arteries. 
 Sublingual administration of misoprostol of second-trimester 
medical abortion results in a higher success rate and does not affect 
umbilical blood flow. 
 
5)   CALISKAN E, DILBAZ S, DOGER E, OZEREN S, DILBAZ B, 
RANDOMIZED COMPARISON OF 3 MISOPROSTOL 
PROTOCOLS FOR ABORTION INDUCTION AT 13-20 WEEKS 
OF GESTATION. J REPROD MED 2005;50(3):173-80. ERRATUM 
IN: J REPROD MED 2005;50(9):732 
Reported that administration of 100 µg of misoprostol sublingually 
every 2 hours was more effective for the induction of second-trimester 
abortion compared with 200 µg of misoprostol vaginally every 4 hours. 
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6)  VIMALA N, DADHWAL V, MITTAL S. SUBLINGUAL 
MISOPROSTOL FOR SECOND-TRIMESTER ABORTION. INT J 
GYNECOL OBSTET 2004;84(1) 89-90. 
 Reported that success rate in using a single dose of 800 µg of 
misoprostol sublingually was 92% . 
 
 
7)  TANG OS, LAU WN, CHAN CC, HO PC, A PROSPECTIVE 
RANDOMIZED COMPARISON OF SUBLINGUAL AND 
VAGINAL MISOPROSTOL IN SECOND TRIMESTER 
TERMINATION OF PREGNANCY. BJOG 2004;111(9):1001-5. 
 Administered  400 µg of misoprostol every 3 hours for a maximum 
of 5 doses either sublingually or vaginally and repeated the regimen if 
patient did not abort within 24 hours. They concluded that the median 
induction to abortion interval was similar in 2 groups and the use of 
vaginal misoprostol had a higher success rate than that of sublingual 
misoprostol for the first 24 hours, but the abortion rate was similar in 48 
hours. 
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8) NAGARIA TRIPTI, SOMAWAR SWATI, The Journal of 
Obstetrics and Gynaecology of India. (2007) 
 To assess the safety and efficacy, complete abortion rate, induction 
abortion interval (IAI) and side effect of misoprostol for voluntary 
termination of second trimester pregnancy. 
 
 Fifty selected women admitted for second trimester (13-22 weeks) 
abortion were administrated 800  µg misoprostol intravaginally followed 
by 300 µg sublingually every 3 hours upto a maximum of 3 doses or till 
abortion if occurred earlier. 
 
 Of the 50 women, 49 aborted with 24 hours of administration of 
vaginal misoprostal giving success rate of 98%. The complete abortion 
rate was 88%. Mean IAI was 9.36 + 3.50 hours and mean dose of 
misoprostol required 1485.63 + 219.25 µg. The mean blood loss was 60.2 
+ 2.01 ml. The main side effects were vomiting, diarrhea, and fever in 
12% each. 
 
 Intravaginal misoprostol (800 µg) followed by sublingual (300 µg 
x 3 hourly) misoprostol is a safe, effective, cheap and acceptable method 
for the second trimester pregnancy termination. 
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 9)  DIABAZ S, et al Department of Obstetrics and Gynaecology, SSK 
Ankara Maternity ,Turkey. 
 They studied 250 women between 12 – 20 weeks of gestation. The 
women received 200 µg vaginally initially followed by 100 µg oral every 
2 hours until expulsion of fetus. The main outcome was expulsion rate 
within 24 hours in 98% of cases. Mean Misoprostol dosage was 200 – 
2100 mcg. Cox regression analysis revealed dead embryo don‟t affect the 
induction abortion time. But induction abortion time tends to be longer in 
the presence of live fetus and with gestational age of older weeks (>16 
weeks) with live fetuses. 
 
10) FARMINGTON USA 
 This study compared 2 different doses of Misoprostol in second 
trimester pregnancy in 40 women. An initial dose of 800 µg of vaginal 
Misoprostol and  regimen of 400 mcg of oral Misoprostol every 8 hours 
is as effective as the same dose of vaginal Misoprostal, with no additional 
side effects. 
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11) RASHMI SHAH, ANITA PEDDAWAD, KAVITA TILWANI, 
BHAGYASHREE KANJE AND RUHI PEDNEKAR, REKHA 
DEVAR, J.J GROUP OF HOSPITALS. (2002 – 2004) 
 A Double Blind Randomized Comparison of Vaginal and 
sublingual Misoprostol regimens for Termination of Pregnancy in the 
Second Trimester (WHO Multicentre Study) of 13 – 20 weeks duration in 
42 women was undertaken. The women are allocated randomly to receive 
the active drug i.e. 400 µg misoprostol administered either vaginally or 
sublingually every 3 hours up to five doses. Side effects are being 
recorded 3 hours during the stay at the hospital and outcome assessed 24 
hours after the start of the treatment. According to this study both vaginal 
and sublingual regimens were equally effective in termination of 
pregnancy second trimester.   
 
12) SHARMA Y,  VIMALA N, DADHWAL V, MITTAL S.  
 A randomized comparison of sublingual and vaginal misoprostol 
for cervical priming before termination of early pregnancy. 
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 ABORTION 
Definition  
 Abortion is defined as the termination of pregnancy after 
implantation of the blastocyst in the endometrium  but before fetus has 
attained viability (i.e.) before 20 weeks of gestation or weight less than 
500 gms. (WHO). 
Types of Abortions: 
 Abortions can be classified as either of the following: 
 Spontaneous 
 Induced  
          Abortion is legalised by MTP ACT 1971. 
 Medical termination of pregnancy means deliberate termination of 
pregnancy before the fetus becomes viable. 
 Second trimester termination of pregnancy means termination of 
pregnancy between 13 to 20 weeks of gestation. 
 
Reproductive Health and Abortion Statistics in India:  
Percent using Family Planning     - 49% 
Population of women of reproductive age(15-49)  - 262,200,00 
Number of Abortions, annually    - 6,700,000 
Percent of maternal mortality caused by unsafe abortion – 89% 
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LEGAL STATUS OF ABORTION IN INDIA 
 According to the IPC Act 1860 induction of abortion was illegal in 
India. In 1964 a committee was set up to examine the old law. The 
committee submitted its report in 1966 recommending liberalization of 
abortion laws to bring down the morbidity and mortality resulting from 
illegal abortion. The MTP bill was enacted in 1971 and come into force in 
1972 April 1
st
. 
MTP Act 
The MTP Act (Act No. 34 of 1971) has been defined in its opening 
lines as An Act to provide for the termination of certain pregnancies by 
registered medical practitioners and to matters connected therewith or 
incidental thereto. 
Passed by Parliament on August 10, 1971, this is a Central Act that 
extends to the whole of India except the state of Sikkim. 
Medical termination of pregnancy was liberalized in Indian with 2 
main objectives. The first objective is to transfer a large number of 
criminal induced abortions with all their inevitable complication from the 
hands of untrained people to the safe hands of skilled and specialized 
obstetricians. The second objective is to aim at the target of population 
control which could not be achieved satisfactorily by the various 
contraceptive methods either due to the failure of individual method or 
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due to the non-adoption of any method by the general and uneducated 
people of our country. 
With the advent of Medical termination of pregnancy the 
liberalization of abortion laws and necessity of family planning have led 
the increased demand for termination of pregnancy through out the world 
in general and in India in particular.  
Consent  
 If married - her written consent. Husband‟s consent not required. 
 If unmarried and above 18years – her own written consent. 
 If below 18years – written consent of her guardian. 
 If mentally unstable – written consent of her guardian. 
 A consent assures the clinician performing the abortion that she: 
 Has been informed of all her options. 
 Has been counseled about the procedure, its risks and how to 
care for herself after she chose abortion of her own free will.  
Person or persons who can perform MTP: physicians qualified to do 
MTP are: 
 Any qualified registered medical practitioner who has assisted in 
25 MTPs. 
 A house surgeon who has done six months post in Obstetrics and 
Gynaecology.  
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 A person who has a diploma/degree in Obstetrics and 
Gynaecology.  
 3 years of practice in Obstetrics and Gynaecology for those doctors 
registered before the 1971 Act was passed. 
 1 year of practice in Obstetrics and Gynaecology for those doctors 
registered on or after the commencement of the Act. 
 Whenever the pregnancy exceeds 12 weeks but is below 20 weeks 
opinion of two registered practitioners is necessary. 
A variety of Induced abortion services are available in India. They are 
1. Government Hospitals and centres. 
2. Municipal Hospitals and Maternity homes. 
3. Recognized Non Governmental organizations. 
4. Recognized Private Hospitals, Nursing Homes and Clinics. 
 
INDICATIONS FOR LEGAL ABORTION: 
 Medical 
 Eugenic 
 Humanitarian 
 Social 
 Contraceptive failure and 
 As family planning procedure.  
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MEDICAL 
Abortion is indicated in pregnant women who has a serious 
medical disease and continuation of pregnancy could endanger her life 
like: 
1. Hypertensive disorders,  
2. Renal disease with high blood urea, 
3. Breast cancer 
4. Cancer cervix  
5. Psychotic illness 
6. Diabetes mellitus with retinopathy 
EUGENIC 
 When there is genetic transmission of mental disease like down 
syndrome, Neural tube anomalies like anencephaly and some cases of 
hereditary and metabolic diseases.  
 It is also indicated when the fetus is likely to be deformed due to 
the action of drugs or exposure to infections or radiation. 
HUMANITARIAN 
 Pregnancy due to rape. 
SOCIAL 
 According to WHO report, this forms the commonest indication in 
the present day medical practice. Pregnancy is terminated to promote not 
-18- 
 
 
only physical or mental health but also for social well being of the 
pregnant women and her family. 
FAILURE OF CONTRACEPTIVE METHODS 
 According to Medical Termination of pregnancy Act, 1971, one 
can request a legal abortion in our country if she conceives due to failure 
of any contraceptive method. 
FAMILY PLANNING PROCEDURES 
 Second trimester abortion is adopted as one of the family planning 
device. 
INCIDENCE  
 About 85% of the induced abortions are in the first trimester and 
15% in the second trimester. Ideally the first trimester termination is 
done, prognosis is better. Morbidity and mortality rates in mid trimester 
are 3-4 times higher than that of the first trimester terminating.  
REASONS FOR DELAY IN SEEKING ABORTION 
1. Lack of information on the availability of abortion facilities. 
2. Ignorance and / or psychological denial of pregnancy. 
3. Ambivalence regarding the desirability of abortion 
4. Late identification of Medical disorders contraindicating the 
continuation of pregnancy. 
5. Late discovery of fetal malformation. 
6. Lack of financial resources to reach the hospitals. 
-19- 
METHODS FOR TERMINATION OF SECOND  
TRIMESTER PREGNANCY 
 
MEDICAL METHODS 
 Extra ovular instillation of drugs. 
a) Ethacridine lactate 0.1% 
b) Hypertonic saline 
c) Prostaglandins (PGE2)  
 
 Intra amniotic instillation of drugs. 
a) Hypertonic saline (20%) 
b) Urea 
c) Prostaglandins  
 
 Extra ovular  administration of drugs. 
a) Prostaglandins ( Oral, vaginal, sublingual (PGE1), parenteral 
(PGF2α) 
b) Oxytocics  
 
 Extra ovular insertion of sterile catheter. 
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MEDICAL METHODS: 
 Ethacradine lactate:( Emcredyl or Rivanol)  
 This drug is introduced through a sterile catheter through 
vagina into uterine cavity and placed in the extra amniotic 
sac.  
 This procedure is not painful, safe and cheap  
 Maximum of 150ml is instilled. 
 Uterine activity begins within 12 to 18hours 
 The mean induction abortion interval varies between 24 and 
36 hours. 
  To hasten the process of abortion, it can be used along with 
prostaglandin or oxytocin.  
 Prostaglandin: 
PGE2:(cerviprime) 
 Prostaglandin in gel form is inserted into cervical canal. 
 Induces uterine contractions within few hours of insertion. 
 Oxytocin can be supplemented. 
 Abortion is usually achieved in less than 24hrs and the 
abortion is complete.  
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PGE1: (MISOPROSTOL) 
 Available in tablet form and given by oral / sublingual or can 
be inserted vaginally. 
 200mg of oral mifepristone (RU486) followed 36 to 48hrs 
later by 600µg misoprostal every 3 hourly with a maximum 
of 5 doses.  
SURGICAL METHODS 
a) Dilatation and evacuation 
b) Aspirotomy 
c) Hysterotomy 
d) Hysterectomy (rare) 
Aspirotomy: 
 Procedure is similar to suction evacuation. 
 To help in dilatation of cervix laminaria tents, prostaglandin 
may be used. 
Hysterotomy: 
  Operative procedure. 
 Under Anesthesia  abdomen  is opened and the contents of 
the uterus is removed directly under vision.  
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Among the various methods, surgical methods compared to 
medical methods have the following disadvantages: 
 Uterine hemorrhage 
 Pelvic infection 
 Cervical injury 
 Uterine perforation 
 Retained products 
 Continuation of pregnancy especially in vacuum aspiration 
cases. 
 Maternal morbidity and mortality may be increased. 
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T. Misoprostol 
  
 
 
MISOPROSTOL PHARMACOLOGY 
 
Misoprostol is a synthetic, PGE1, analogue (15-deoxy – 16-hydroxy 
– 16-methyl PGE1), initially developed for the prevention and treatment 
of peptic ulcer is found to have uterotonic and cervical ripening effects as 
well. It is cheap, stable at room temperature and can be stored for a long 
time. The oral tablets are effective in different routes administration. 
Misoprostol in the required doses had only few (dose-dependent) side 
effects, and it is readily available in many countries. 
 
Mechanism of Action 
 Misoprostol is actively absorbed, Primarily metabolized in liver 
and get converted into active plasma metabolite called Misoprostolic 
acid.  
 Misoprostol is a myometrial stimulant which binds to E-2 and E-3 
prostanoid receptors and cause effective uterine contraction and ripening 
of cervix. 
 
13)  O.S.TANG, K.GEMZELL-DANIELSSON, P.C HO 2007 
Misoprostol: Pharmacokinetic profiles, effects on the uterus and 
side-effects. 
 Misoprostol, a synthetic prostaglandin E1 analogue, is commonly 
used for medical abortion, cervical priming, the management of  
-24- 
  
 
 
 
 
 
The structure of misoprostol and naturally occurring 
prostaglandin (PGE1). 
 
  
 
 
miscarriage, induction of labor and the management of postpartum 
hemorrhage. 
 
Structure And Chemistry Of Misoprostol 
 Misoprostol differs structurally from natural prostaglandin E1 by 
the presence of a methyl ester C-1, a methyl group at C-16 and a 
hydroxyl group at C-16 rather than at C-15. The methyl ester at C-1 
increases the anti-secretary potency and duration of action of misoprostol, 
whilst the movement of the hydroxyl group from C-15 to C-16 and the 
addition o f a methyl group C-16 improves oral activity, increases the 
duration of action, and improves the safety profile of the drug. 
 
Pharmacokinetic properties of the various routes of administration of 
misoprostol 
 Misoprostol tablets were used in following routes  
1.Oral  
2.Vaginal  
3.Sublingual  
4.Buccal  
5 Rectal. 
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Mean plasma concentrations of misoprostol acid over time (arrowbars = 1 SD). 
[Tang. Pharmacokinetics of different routes of administration of misoprostol. 
Hum Reprod 2002. Reproduced by permission of Oxford University Press]. 
 
 
  
 
 
 Oral route 
After oral administration misoprostol is rapidly and almost 
completely absorbed from the gastrointestinal tract. However, the 
drug undergoes extensive and rapid first-pass metabolism (de-
esterification) to form misoprostol acid. Following a single dose of 
400 µg oral misoprostol , the plasma misoprostol level increases 
rapidly and peaks at about 30 minutes (Fig) declines rapidly by 120 
minutes and remains low thereafter. 
 
 Vaginal route 
The plasma concentration increases gradually after vaginal 
administration, reaching its maximum level after 70-80 minutes 
before slowly declining with detectable drug levels still present after 
6 hours. 
 Although the peak concentration after oral administration is higher 
than for vaginal administration, the „area under the curve‟ is higher 
when given vaginally. The greater bioavailability of vaginal 
misoprostol may help to explain why it is more effective in medical 
abortion. 
 It has been shown that the coefficient of variation of the AUC after 
vaginal administration is greater than that after oral administration. 
This means that the vaginal absorption of misoprostol is inconsistent. 
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In clinical practice, remnants of tablets are sometimes seen many 
hours after vaginal administration, indicating that the absorption is 
variable and incomplete. This may be due to variation between 
women in the amount of pH of the vaginal discharge. Variation in the 
amount of bleeding during medical abortion may also affect the 
absorption of misoprostol through the vaginal mucosa. The addition 
of water to the misoprostol tablets is a common practice. However, 
this has been shown not to improve the bioavailability of vaginal 
misoprostol. 
 
 Sublingual route 
Misoprostol tablet is very soluble and can be dissolved in 20 
minutes when it is put under the tongue. Sublingual misoprostol has 
the shortest time to peak concentration, the highest peak 
concentration  and the greatest bioavailability when compared to 
other routes. 
The peak concentration is achieved in about 30 minutes after 
sublingual and oral administration, whereas following vaginal 
administration, it takes 75 minutes. After 400 µg of misoprostol, a 
sublingual does achieves a higher peak concentration than that of oral 
and vaginal administration. This is due to rapid absorption through 
the sublingual mucosa as well as the avoidance of the first-pass  
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Mean serum levels of misoprostol acid in pg/mL for four epithelial routes of 
misoprostol administration over 5 hours. Error bars represent standard 
deviation. [Meckstroth. Misoprostol Absorption and Uterine Response. 
Obstet Gynecol 2006. Reproduced by permission of Lippincott Williams & 
Wilkins]. 
 
 
 
  
metabolism via the liver. The abundant blood supply under the 
tongue and the relatively neutral pH in the buccal cavity may be 
contributing factors. The rapid onset and high peak concentration 
means that of all the possible routes the systemic bioavailability, as 
measured by the AUC in the first 6 hours is greatest of sublingual 
administration. 
 Although vaginal absorption has been shown to be slower 
and the peak concentration lower than that for the other routes, the 
serum level of misoprostol is sustained at the low level for a longer 
period of time. Therefore, the effect of misoprostol may linger for 
more than 6 hours after a single dose, though the threshold serum 
level for clinical action is unknown. 
  
 Buccal route 
  Buccal administration, the drug is placed between the teeth 
and the check and allowed to be absorbed through the buccal mucosa. 
         The shape of the buccal route absorption curve is very similar 
to that for vaginal absorption but the serum drug levels attained are 
lower throughout the 6 hours study period. 
 After buccal administration the Tmax is 75 minutes which is 
similar to that after vaginal administration, but the AUC of buccal 
administration is just half that of the vaginal administration. 
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 Rectal  route 
The rectal route of administration has been studied recently for the 
management of postpartum hemorrhage. This route of administration is 
less commonly used for the other applications. The shape of the 
absorption curve after rectal administration is similar to that of vaginal 
administration but its AUC is only 1/3 that of vaginal administration. The 
mean Tmax after rectal administration is 40-65 minutes. 
Sublingual misoprostol, which has the shortest Tmax, is perhaps 
useful for clinical applications that require a fast onset of clinical action, 
such as postpartum hemorrhage or cervical priming. Vaginal misopostol 
on the other hand, which has a high bioavailability and sustained serum 
level, is useful for indications that require longer time for the 
manifestation of its clinical effects, like medical abortion. 
 
Route  Onset of action Duration of action 
Oral 8 min 2 hours 
Sublingual  11 min 3 hours 
Vaginal 20 min 4 hours  
Rectal  100 min 4 hours 
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 EFFECTS 
 Uterus 
After a single dose of oral misoprostol there is an increase in uterine 
tonus. To produce regular contraction, however, a sustained plasma 
level of misoprostol is required and this required repeated oral dose. 
  The mean time to increase in tonus is 8 and 11 min for oral 
and sublingual administration respectively compared with 20 mins for 
vaginal administration. The mean time to maximum tonus is also 
significantly shorter for oral and sublingual misoprostol compared to 
vaginal administration. One to two hours after the administration of 
misoprostol, the tonus begins to decrease. In the case oral 
misoprostol, this is the end of the activity. For vaginal and sublingual 
treatment, however, the tonus is slowly replaced by regular uterine 
contractions. These regular uterine contractions are sustained for a 
longer period after vaginal administration than after sublingual 
treatment, with decreased activity occurring only after 4 hours 
(compared to 3 hours with sublingual). 
 
 Cervix 
Misoprostol has been used extensively for its cervical softening 
effect before induction of labour and surgical evacuation of the 
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uterus. It is more likely to be due to the direct effect of misoprostol 
on the cervix. The exact mechanism leading to physiological 
cervical ripening is not known. The biochemical events that have 
been implicated in cervical ripening are decrease in total collagen 
content and increase in collagen solubility, and an increase in 
collagenolytic activity. Action of misoprostol appeared to be 
mainly on the connective tissue stroma with evidence of 
disintegration and dissolution of collagen. 
 
 Gastrointestinal effects: 
 Misoprostol has gastric antisecretory effects and mucosal 
protective effect. Misoprostol is effective in preventing NSAIDS 
induced gastric ulcer. 
 
Side effects: 
Misoprostol is a safe and well-tolerated drug. Pre-clinical 
toxicological studies indicate a safety margin of at least 500 – 1000 fold 
between lethal doses in animals and therapeutic doses in humans. No 
clinically significant adverse hematological, endocrine, biochemical, 
immunological, respiratory, ophthalmic, platelet or cardiovascular 
effects have been found with misoprostol.  
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 Gastro – intestinal side effects like diarrhea, 
abdominal pain, nausea, flatulence, dyspepsia, 
headache, vomiting and constipation. 
 Shivering 
 Hyperthermia 
 Dizziness 
 Pelvic Pain 
 Severe genital bleeding 
 Pain due to uterine contraction  
 Uterine rupture  
Over dosage can cause sedation, tremor, convulsion, dyspneoa, 
abdominal pain, diarrhea, fever, palpitation or bradycardia. Symptoms 
should be treated with supportive therapy. 
Contraindications to the use of misoprostol  
 Cardiac disease 
 Renal disease 
 Hypertension  
 Bronchial asthma 
 Previous caesarean scar  
 Hepatic failure 
14) ARONSSON et al. 
The increase in uterine tonus is more rapid and more pronounced 
following oral and sublingual treatment than after vaginal treatment. 
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MATERIALS AND METHODS 
  
MATERIALS AND METHODS 
 
 This study was carried out in the Family welfare unit of 
Department of obstetrics & gynaecology, Government Rajaji Hospital, 
Madurai during the period of March 2010 to November 2010. 
 The purpose of this study is to compare the efficacy of sublingual 
and vaginal routes of misoprostol administration for medical abortion in 
the second trimester. 
Study population: 
 100 women requesting pregnancy termination at 12- 20 weeks of 
gestational age were randomly selected for the study. This includes from 
all age groups, parity and socioeconomic status.  
Exclusion criteria  
Patients with following are excluded  
 Bronchial asthma 
 Hemorrhagic Disorders 
 Cardiac diseases 
 Renal disease 
 Jaundice 
 Scarred uterus  
They were grouped into two 
 50 patients  - Group A  :  Sublingual misoprostol 
 50 patients  - Group B  :  Vaginal misoprostol 
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Informed Consent: 
 Written consent of the patients were taken and if patient was a 
minor, her parent‟s consent was obtained. Patient was given prophylactic 
antibiotics. 
Preparation of patients: 
 On admission, complete history was taken. General examination 
and systemic examination were carried out. 
 Abdominal examination and bimanual pelvic examination was 
done. By speculum examination any torn, cicatrized cervix 
ruled out. 
 Patient was instructed about the method and side effect of the 
drug. 
Investigations: 
 Urine  -  Albumin 
Sugar 
Deposits  
 Haemoglobin 
 Blood grouping & Rh typing  
 Bleeding time 
 Clotting time 
 Blood urea, sugar, serum creatinine 
 Ultrasonogram 
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METHODOLOGY 
 
Group A: 
400 g of misoprostol (2x200g tablets) was given sublingually, 
and repeated every 4 hours until abortion or to a maximum of 6 doses. 
 Patients in this group were asked not to eat or drink for 20 
minutes following administration of the drug. 
 
Group B: 
 Under aseptic precaution, patient in dorsal position, with speculum 
the posterior lip of cervix was visualized and 400g of misoprostol 
soaked in normal saline was kept in the posterior fornix and the patient 
was instructed to stay in bed for 30 minutes. Dose was repeated every 
4hours until abortion or to a maximum of 6 doses. 
 In each case, the following parameters were recorded 
 Time of application of tablets 
 Monitoring of pulse, blood pressure and temperature (hourly) 
 Progress of  abortion assessed 
 Interval between induction and onset of  active labour (hours) 
 Interval between induction and abortion in hours 
 Duration of oxytocin acceleration in hours. 
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 Patients were carefully monitored for development of symptoms  
- Nausea 
- Vomiting 
- Fever 
- Diarrhoea 
If the patients did not get aborted within 24 hours, it was taken as 
failed induction.  They were treated with second course of misoprostol or 
hysterotomy. 
After expulsion of product of conception, check curettage was 
routinely done for all cases. 
 Haemoglobin was rechecked after 48 hours. 
 
Follow up: 
 Patient was advised to come for the follow up at the end of one 
month and at the end of 3 months to enquire about the menstrual 
regularity and general status. 
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STATISTICAL TOOLS 
 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008) 
developed by Centre for Disease Control, Atlanta.  
 
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and 
 
'p'  values were calculated. Kruskul 
Wallis chi-square  test was used to test the significance of difference 
between quantitative variables. A 'p' value less than 0.05 is taken to 
denote significant relationship. 
 
  
-37- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANALYSIS OF STUDY 
 
 ANALYSIS  OF STUDY 
    
100 cases: 
 Group A  – SUBLINGUAL MISOPROSTOL  – 50 CASES 
 Group B   –  VAGINAL MISOPROSTOL        – 50 CASES. 
Analysis was done in the following aspects. 
 Distribution of age 
 Socio economic status 
 Parity distribution 
 Gestational age 
 Induction abortion interval 
 Induction outcome 
 Induction outcome and age 
 Induction outcome and parity 
 Side effects 
 Change in Hemoglobin value 
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RESULTS   
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Table 1: Age distribution 
 
Age in years No of Cases in 
Sublingual Group A Vaginal Group B 
No % No % 
Less than 20 years 1 2 2 4 
20 - 24 years 17 34 17 34 
25 – 29 years 18 36 19 38 
30 – 34 years 11 22 8 16 
35 years & above 3 6 4 8 
Total 50 100 50 100 
Range 
Mean 
S.D 
18 – 37 years 
26.7 years 
4.5 years 
19 – 35 years 
26.4 years 
4.4 years 
„P‟ 0.727 Not Significant 
 
 Comparing the age distribution in both the groups, majority of the 
patients were between 20-29 years of age 70% (35/50) in Group A and 
72% (36/50) in Group B. Teenage group contributes to minority of the 
population 2% (1/50) in Group A and 4% (2/50) in Group B. 
  
 There is no statistically significant difference in mean age in both 
groups. 
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Table 2: Socio Economic Status 
 
 
Socio Economic 
Status 
  
Sublingual Group A Vaginal Group B 
No % No % 
I Nil Nil Nil Nil 
II Nil Nil Nil Nil 
III Nil Nil Nil Nil 
IV 29 58 27 54 
V 21 42 23 46 
Total 50 100 50 100 
„P‟ 0.8403 Not Significant 
 
 
 There is no statistically significant difference between the 
socioeconomic status of two groups. All the cases belong to the lower 
strata of the society. 
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Table 3: Parity 
 
 
Parity 
  
Sublingual Group A Vaginal Group B 
No % No % 
Primi 7 14 8 16 
Multi 43 86 42 84 
„P‟ 0.7805 Not Significant 
 
 
 The difference in the Parity of the two groups of patients is not 
statistically significant. 
  
 Most of the patients were multigravida 86% (43/50) in Group A 
and 84% (42/50) in Group B. 
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Table 4: Gestational Age in weeks 
 
Gestational Age 
(in weeks) 
  
Sublingual Group A Vaginal Group B 
No % No % 
12- 16 weeks 28 56 33 66 
17- 20 weeks 22 44 17 34 
Total 50 100 50 100 
Range 
Mean 
S.D 
13 – 20 weeks 
16.4 weeks 
2.4 weeks 
13 – 20 weeks 
16.2 weeks 
2.6 weeks 
„P‟ 0.5029 Not Significant 
 
 The mean Gestational age of both groups is not significantly 
different. (P value is 0.5029) 
  
-42- 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-  
 
 
 
Table 5: Induction abortion interval ( in hours) 
 
Induction abortion 
interval  
(in hours) 
  
Sublingual Group A Vaginal Group B 
No % No % 
Up to 6 hours 4 8 1 2 
6.1 - 12 hours 27 54 12 24 
12.1 - 18 hours 10 20 16 32 
18.1 - 24 hours 6        12 16 32 
Failed Induction 3 6 5 10 
Total 50 100 50 100 
Range 
Mean 
S.D 
5.5 – 24 hours 
11.4 hours 
4.9 hours 
5.16 – 23 hours 
15.4 hours 
5.0 hours 
„P‟ 0.0001 Significant 
 
 The mean induction abortion Interval in Group A is                           
11.4 + 4.9hours and that of Group B is 15.4 + 5 hours. 
  
 The induction abortion interval is shorter in sublingual misoprostal 
Group A than Vaginal misoprolstal Group B and the difference is 
statistically significant. 
(p=0.0001) 
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Table 6: Induction Outcome 
 
 
Induction outcome 
  
Sublingual Group A Vaginal Group B 
No % No % 
Success 47 94 45 90 
Failure 3 6 5 10 
„P‟ 0.3575 Not Significant 
 
 
  
 Success rate is slightly high in Group A 94% (47/50) than Group B 
90% (45/50) but it is not statistically significant (P = 0.3575 ). 
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Table 7: Induction Outcome and age 
 
 
Induction outcome 
Age in Years 
Range Mean S.D 
Success 18 – 37 years 26.8 4.6 
Failure 20 – 28 years 24.3 2.5 
„P‟ 0.1215 Not Significant 
 
 
 
 There is no statistical significance of age in relation to induction 
outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-45-  
  
 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
Table 8: Induction Outcome and Parity 
 
 
Parity 
Induction outcome 
Success Failure 
No % No % 
Primi (15) 13 86.7 2 13.3 
Multi (85) 79 92.9 6 7.1 
„P‟ 0.3435 Not Significant 
 
 
 
 There is no statistical significance of parity in relation to induction 
outcome. 
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Table 9: Side Effects 
 
 
Side Effects 
  
Sublingual Group A Vaginal Group B 
No % No % 
Fever - - 3 6 
Diarrhea 2 4 3 6 
Vomiting 3 6 1 2 
Total with 
Complication 
5 10 7 14 
Total without 
Complication 
45 90 43 86 
„P‟ 0.7583 Not Significant 
 
Side effects are present in 10% (5/50) in Group A and 14% (7/50) in 
Group B. 
 
 There is no statistically significant difference in side effects 
between two groups. 
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Table 10: Changes in Hemoglobin (gm%) at Induction and after 
expulsion 
 
Hemoglobin gm% Sublingual  Group A Vaginal Group B 
Mean SD Mean SD 
 
At Induction 
 
9.04 
 
0.46 
 
9.22 
 
0.45 
 
After expulsion 
 
9.01 
 
0.45 
 
9.18 
 
0.44 
 
Change in Hb% 
 
0.03 
 
0.1 
 
0.04 
 
0.1 
 
      P Value 0.3423 (Not. Significant) 
 The change in Hemoglobin value in both groups before and after 
expulsion is not statistically significant.  
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DISCUSSION 
  
 
 
DISCUSSION 
 
 There are variety of medical and surgical techniques for 
termination of pregnancy. Second trimester abortion constitutes 15% of 
all induced abortion. During the last decade, medical methods for second 
trimester abortion have become safe and more considerable. Uterine 
evacuation by medical methods reduces the morbidity associated with 
surgical intervention. 
 
 Cervical ripening and uterotonic effects of prostaglandin (PGE1  
analogue - MISOPROSTOL) is effectively utilized  in this study for non 
invasive expulsion of products of conception.  
 
 Here this study was conducted in Department of Obstetrics and 
Gynaecology, Government Rajaji Hospital, Madurai to assess the 
efficacy, side effects and acceptability of sublingual and vaginal 
misoprostal in second trimester termination of pregnancy. 
 
 In this study 50 patients were given 400 µg sublingual misoprostol. 
 Another 50 patients were given 400 µg vaginal misoprostol. 
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1. AGE:- 
 In our present study majority of the patients in both groups are 
between 20 – 29 years of age. The mean age is (26.7 + 4.5) in sublingual 
group and (26.4 + 4.4) in vaginal group, and is not a statistically 
significant difference. 
 This results is similar to that of the study by                             
KOUDAG et al.,(2009)  
 
2. SOCIO-ECONOMIC STATUS:- 
 All the patient in the present study belong to low socio-economic 
status (Grade IV and Grave V). There is no statistically significant 
difference in Socio-economic status between sublingual and vaginal 
group. 
 
3. PARITY:- 
 In the present study most of the patients are multigravida 86% 
(43/50) in sublingual group and 84%(42/50) vaginal group. 
 The difference in the parity of the two groups is not statistically 
significant. (p value is 0.7805). 
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4. GESTATIONAL AGE IN WEEKS:- 
 The Range of Mean gestational age of both sublingual and vaginal 
group is 13 weeks to 20 weeks. 
 There is no statistically significant  (p=0.5029) difference in both 
group with regard to gestational age. 
 In the present study there is no statistically significant difference in 
maternal age, parity and gestational weeks, which is similar to the study 
conducted by A.YASEMNIN KARAGEYIM KARSIDAG et al., (2009) 
 
5. INDUCTION ABORTION INTERVAL:- 
In the present study the mean interval between start of induction and 
vaginal delivery is shorter in the sublingual group 11.4 hours than vaginal 
group 15.4 hours and this difference is statistically significant. 
(p=0.0001). In (27/50) 54% of Sublingual group Induction Abortion 
Interval is 6.1 to 12 hours. 
 This result is compatible with the study conducted by a 
A.YASEMIN, ESRA, BALINT RAMZAN(2009) on vaginal versus 
sublingual misoprostol for second-trimester pregnancy termination and 
effect on Doppler measurements. In their study mean induction abortion 
interval in sublingual group 12.8 hours and vaginal group is 22 hours and 
was statistically significant. 
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6. INDUCTION OUTCOME:- 
 In the present study the success rate is 94% (47/50)in sublingual 
group and 90% (45/50) in vaginal group. There is no statistically 
significant difference in success rate between sublingual and vaginal 
group. Thus both sublingual and vaginal misoprostol  is equally effective 
in inducing second trimester abortion. 
 
 This results is similar to study conducted by BHATTACHARJEE : 
SHYAMA PRASA SAHA : SAMEI CHANDRA GHOSTRY (2008) Their 
study concluded as both sublingual and vaginal administration of 
misoprostol are equally effective in inducing medical abortion during 
second trimester. 
 
 The study by CALISKAN et al(2005) Showed sublingual 
administration of misoprostol for second trimester abortion results in a 
higher success rate than vaginal misoprostol. 
 
 Tang et al study  (BJOG:2004) showed vaginal misoprostol had a 
higher success rate than that of sublingual misoprostol for first 24 hours 
but the abortion rate was similar in 48 hours. 
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 Failure rate is 6% (3/50) in sublingual group and 10% (5/50) in 
vaginal group. Those patients who were not aborted after 24 hours were 
reassured and further treated with one of the following measures. 
Methods No. of Patients 
Sublingual Vaginal 
Second Course of Misoprostol 2 2 
Bougie insertion - 2 
Hysterotomy 1 1 
Total cases 3 5 
 
7. INDUCTION OUTCOME AND AGE:- 
  There is no statistical significance of age in relation to 
Induction outcome. 
8. INDUCTION OUTCOME AND PARITY:- 
  The success rate is 86.7% in Primi and 92.9% in 
Multigravida. 
  There is no statistical significance of parity in relation to 
Induction outcome (P=0.3435)    
HELENA VON HERTZEN1 et al., (2008) their study suggested that 
equivalence could not be made between sublingual and vaginal group in 
inducing second trimester abortion. Vaginal administration showed a 
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higher effectiveness than sublingual administration in termination second 
trimester pregnancies but this result was driven mainly by 
NULLIPAROUS Women.  
9. SIDE EFFECTS:- 
 Diarrhea occurred in 2 patients of sublingual group and 3 
patients of vaginal group. 
 Fever occurred in 3 patients of vaginal group. 
 Vomiting occurred in 3 patient of sublingual group and 1 
patient of vaginal group. 
Thus side effects occurred in less number of patients (12/100 patient) 
 There is no statistically significant difference in side effect between 
two groups. 
 A.YASEMIN KARAGYIN KARSIDAG et al.,(2009) in this study 
there is no statistically significant difference between sublingual an 
vaginal group. In this study the side effects were nausea, vomiting, 
diarrhea and fever. 
 BHATTACHARJEE NABENDU et al., (2008) in this study the 
difference in the incidence of side effects were statistically in significant 
between two groups.  
 The result of the present study is similar to the above studies. 
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TANG OS, LAU WN, CHAN CC, HO PC et al., (2004),                     
ARONSSON A et al., (2004), 
 In the above three study Sublingual Misoprostol was associated 
with a higher incidence of adverse effects especially diarrhea, fever and 
chills. 
10. CHANGE IN HEMOGLOBIN VALUE (GM%):- 
 The mean hemoglobin at induction is 9.04 gm in sublingual group 
and 9.22 gm in vaginal group. 
 The mean Hemoglobin after expulsion is 9.01 in sublingual group 
and 9.18 in vaginal group. 
 The change in Hemoglobin value before and after expulsion is not 
statistically significant between sublingual and vaginal group. 
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SUMMARY 
  
 
 
SUMMARY 
 This study „A‟ Prospective comparative study of sublingual versus 
vaginal misoprostol in second trimester termination of pregnancy is 
conducted in Department of Obstetrics and Gynaecology in Madurai 
Medical College, Madurai. The result of the analysis of the study is 
summed up as follows: 
Group A- Sublingual misoprostol – 50 patients  
Group B- Vaginal misoprostol – 50 patients     
 70% of the patients were between 20- 29 years of age in sublingual 
and 72%  in vaginal group. 
 All patients belong to lower socio-economic status.  
  86% of the patients were multigravida  in sublingual group and 
84%  in vaginal group.  
 Mean gestational age is (16.4 + 2.4 weeks) in sublingual group and 
(16.2 + 2.6 weeks) in vaginal group. 
 There is no statistically significant difference in age, socio 
economic status parity and gestational age in weeks between 
sublingual and vaginal misoprostol groups.   
 Induction to Abortion interval is shorter in sublingual group            
(11.4 + 4.9 hours) than vaginal group (15.4 + 5 hours) and is 
statistically significant.  
 There is no statistically significant difference in success rate 
between sublingual and vaginal group .  
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 There is no statistical significance of age in relation to Induction 
outcome. (p = 0.1215) 
 There is no statistical significance of parity in relation to Induction 
outcome.(p = 0.3435) 
 Side effects occurred in less number of patients. 10%  in sublingual 
group and 14%  in vaginal group. 
 The change in Hemoglobin value before and after expulsion is not 
statistically significant between sublingual and vaginal group.   
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CONCLUSION 
  
CONCLUSION 
 
 Misoprostol is equally effective in both sublingual and vaginal 
route in inducing second trimester abortion. 
 
  Expulsion is more rapid with sublingual misoprostol than vaginal 
misoprostol.  
 
 Misoprostol is a safe drug with minimal side effects. 
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PROFORMA 
  
 
 
A PROSPECTIVE COMPARATIVE STUDY OF SUBLINGUAL  
VERSUS VAGINAL MISOPROSTOL IN SECOND TRIMESTER 
TERMINATION  
OF PREGNANCY 
 
 
 
NAME:    AGE:       OBSTETRIC CODE: 
 
LMP:      GESTAIONAL AGE IN WEEKS: 
 
SOCIO ECONOMIC CLASS         : 
 
INCLUSION CRITERIA                 -  Second Trimester (12 - 20wks) medical abortion  
                    (Requested termination / congenital anomalies) 
EXCLUSION CRITERIA 
 Bronchial asthma 
 Hemorrhagic disorders 
 Cardiac disease 
 Renal disorder 
 Jaundice  
 Scarred uterus 
 Known allergy to prostaglandin  
 
GENERAL EXAMINATION             SYSTEMIC EXAMINATION 
PR   BP    CVS 
TEMP:      RS 
INVESTIGATIONS: Hb%   Blood Sugar:  CT :           USG: 
 
                                       Urea:  BT : 
      
Sr Creatinine: 
 
OBSTETRIC EXAMINATION: 
 P/A  Uterus Size    FH 
 
 S/E                                                       P/V       Cervix  
Serial No:             Name Code:    Hospital No.: 
Date of Admission:            Date of Expulsion:  Date of Discharge: 
Group  A: Sublingual misoprostol 400 g every 4 hrs 
Group  B: Vaginal misoprostol 400 g every 4 hrs 
 
Time of Administration of First dose of Misoprostol: 
Time of onset of Uterine contraction: 
 
 Group A  
(Sublingual) 
Group B 
(Vaginal) 
No. of Misoprostol Doses 
 
 
 
Interval between induction and onset of 
active labour (hrs) 
 
  
 
Interval between induction and abortion in 
(hrs) 
 
  
 
Duration of Oxytocin acceleration (hrs) 
 
  
 
Time of expulsion  : 
 
Outcome  : 1) Success (expulsion of products of conception within  
   24hrs of misoprostol administration)  
 
2) Failed induction 
Side effects  : 
 Group A Group B 
Vomiting / Nausea   
Tachycardia   
Diarrhea   
Fever   
Headache   
Post partum hemorrhage   
 
Hb % after expulsion :  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
GROUP - A                SUBLINGUAL 
S.NO NAME AGE IP.NO S.C 
OBST. 
CODE 
GEST. 
AGE  
IN WKS 
HB IN GM%  
AT 
INDUCTION 
INDUCTION 
ABORTION 
INTERVAL 
COMPLI- 
CATION 
HB IN GM%  
AFTER 
EXPULSION 
1 DHANAM 24 002215 IV G2P1L1 14 WKS 9.8 GMS 5 HRS 30 MIN   9.8 GMS 
2 DEVI 30 002270 IV G4P3L3 14 WKS 8.8 GMS 10 HRS30 MIN   8.8 GMS 
3 PANDIAMMAL 28 002726 V G4P3L3 13 WKS  9 GMS 9HRS     9 GMS 
4 SELVI 30 002778 IV G3P2L2  18 WKS 8.8 GMS 5 HRS 30 MIN   8.8 GMS 
5 RAJESHWARI 27 030273 V G5P3L3A1  20 WKS 8.6 GMS 8HRS 25MIN   8.6 GMS 
6 PALKANI 30 002973 IV G4P3L3  16 WKS 9 GMS 18HRS 30 MIN VOMITING 8.8 GMS 
7 MURUGESHWARI 22 003337 V G2P1L1  18 WKS 8.2 GMS 9 HRS    8.2 GMS 
8 RAJI 23 036789 IV G3P2L2  18 WKS  8.4 GMS 24HRS   8.4 GMS 
9 SIVANAMMAL 32 043214 V G2P1L1  20 WKS 8.2 GMS 10HRS    8.2 GMS 
10 SIVAGAMI 27 036786 IV G5P4L4 18 WKS 9.4 GMS 9 HRS    9GMS 
11 MUNIAMMAL 25 036788 IV PRIMI  
14-16 
WKS  
8.4 GMS FAILED INDUCTION   VOMITING 8.4 GMS 
12 MEKALA 26 003893 V G3P2L2 14 WKS  9.4 GMS 6 HRS    9.4 GMS 
13 KALAVATHY 37 040788 IV G3P2L2  19 WKS 8.8 GMS 8HRS 30 MIN   8.8 GMS 
14 MUTHUPANDI 34 041525 IV G3P2L2  16 WKS 9 GMS 12HRS    9 GMS 
15 KALAVATHY 27 041527 IV G3P2L2 18 WKS 9.4 GMS 20 HRS45MIN DIARREA 9.4 GMS 
16 KALEESHWARI 26 041623 IV G2P1L1 16 WKS 9.8GMS 17HRS 30 MIN   9.4GMS 
17 PUSHPAVALLI 25 004609 V G3P2L2  
14-15 
WKS  
8.6 GMS 7HRS 30 MIN   8.6 GMS 
18 RADHA 28 004728 V G3P2L2  14 WKS  8.8 GMS 8HRS    8.8 GMS 
19 VALLI 20 050213 IV PRIMI  17 WKS 8.8 GMS FAILED INDUCTION    8.8 GMS 
20 BHUVANESHWARI 21 004838 IV G3P2L2 13 WKS   9.2 GMS 7HRS    9.2 GMS 
21 REENA 27 051354 V G2P1L1  14 WKS 8.6 GMS 14 HRS 30 MIN   8.6 GMS 
22 PUSHPAVALLI 22 053549 IV PRIMI 20 WKS 9 GMS 18HRS    9 GMS 
23 GOWTHAMY 20 005380 IV G2P1L1 14 WKS 9.2 GMS 7 HRS30 MIN   9.2 GMS 
24 PAVUNTHAI 32 05564 V G3P2L2 14 WKS   8.8 GMS 7 HRS30 MIN   8.8 GMS 
25 RAMUTHAI 27 005566 IV G4P3L3  18 WKS  9 GMS 7 HRS30 MIN   9 GMS 
 
 
26 RATHIDEVI 32 005586 V G3P2L2 14 WKS 9 GMS 7 HRS30 MIN   8.6 GMS 
27 BASURA BEGAM 23 005685 V G2P1L1 18 WKS 9.2 GMS 15HRS    9.2 GMS 
28 LEELA 25 005712 IV G4P3L3 14 WKS 9 GMS 12 HRS 30 MIN   9 GMS 
29 SUMATHY 29 005718 IV G3P2L2 15 WKS 8.6 GMS 8 HRS 45 MIN   8.6 GMS 
30 BACKIALAKSHMI 25 005800 V G4P3L3  18 WKS  9 GMS 13 HRS45 MIN   9 GMS 
31 KALAIVANI 30 05847 IV G4P2L2A1  18 WKS  8.8 GMS 20 HRS 30 MIN   8.8 GMS 
32 SAKILA BANU 34 005901 V G4P3L3 18 WKS 9 GMS 22 HRS 30 MIN DIARREA 9 GMS 
33 NATHIYA 24 006000 IV G3P2L2 13 WKS 9.6 GMS 9 HRS 15 MIN   9.6 GMS 
34 MUTHUMARI 28 006261 V G3P2L2 16 WKS 9.2 GMS 7HRS    9.2 GMS 
35 MAHALAKSHMI 22 006266 IV G2P1L1 20 WKS 10.4 GMS FAILED INDUCTION   VOMITING 10.4 GMS 
36 GEKCHI PRIYADHARSHINI 29 006363 IV G3P2L2 16 WKS 9.2 GMS 9HRS 30 MIN   9.2 GMS 
37 VIJAYALAKSHMI 33 006379 V G3P1L1A1 14 WKS 9 GMS 21HRS    9 GMS 
38 PREETHI 18 006615 IV PRIMI  16 WKS  9.4 GMS 11 HRS 30 MIN   9.4 GMS 
39 ROSI 29 007575 V G3P2L2 20 WKS 8.8 GMS 11 HRS 30 MIN   8.8 GMS 
40 KAVITHA 30 069826 IV G4P2L2A1 14 WKS 9.2 GMS 7HRS    9.2 GMS 
41 MANJULA DEVI 23 008729 IV PRIMI  18 WKS 8.2GMS 13HRS45 MIN   8.2GMS 
42 SANGEETHA 21 008107 V PRIMI 20 WKS 9 GMS 10HRS45 MIN   9 GMS 
43 VALLI 21 008126 IV G2P2L2A1 16 WKS 9 GMS 13 HRS    9 GMS 
44 REVATHY 28 008027 V G4P3L3 16 WKS 8.8 GMS 9 HRS30MIN   8.8 GMS 
45 MURUGA PRIYA 22 008243 V PRIMI 14 WKS 10 GMS 7HRS15MIN   10 GMS 
46 NAGALAKSHMI 23 008391 IV G3P2L2 20 WKS 9.4 GMS 12HRS15MIN   9.4 GMS 
47 JEYA 36 008679 V G3P2L2 14 WKS 9.2 GMS 6HRS30 MIN   9.2 GMS 
48 AMUTHA 35 008960 IV G2P1L1 20 WKS 8.6 GMS 13 HRS20 MIN   8.6 GMS 
49 SUDHA 23 009368 V G2P1L1 14 WKS 9.8GMS 11 HRS30 MIN   9.8GMS 
50 MALARKODI 24 009439 IV G3P2L2  20 WKS 9.4 GMS 6HRS    9.4 GMS 
 
 GROUP - B          VAGINAL 
S.NO NAME AGE IP.NO S.C 
OBST. 
CODE 
GEST. 
AGE  
IN WKS 
HB IN GM%  
AT 
INDUCTION 
INDUCTION ABORTION 
INTERVAL 
COMPLI- 
CATION 
HB IN GM%  
AFTER EXPULTION 
1 MAHALAKSHMI 35 001318 IV G3P2L2 20 WKS 9.4 GMS 17 HRS 15 MIN   9.4 GMS 
2 VIJAYARANI 32 001629 V G4G3L3 14 WKS 9.8GMS 16 HRS   9.6GMS 
3 GOWRI 35 001689 IV G4P3L3 14 WKS 10 GMS 15HRS    10 GMS 
4 KAMATCHI 32 001691 V G4P3L3 16 WKS 10GMS 23 HRS   10 GMS 
5 MEENA 28 018928 IV G3P2L2 18 WKS 9.2 GMS 19 HRS 30 MIN   9.2 GMS 
6 LAKSHMI 29 020601 V G2P1L1 18 WKS 8.6 GMS 23HRS    8.6 GMS 
7 VASIAMMAL 28 000885 IV G1P3L3 14 WKS 9.2 GMS 9 HRS45 MIN   9.2 GMS 
8 LOHESHWARI  30 002727 IV G3P3L2 14 WKS 9.4 GMS 9HRS45 MIN   9.4 GMS 
9 LAKSHMI 23 002818 V G2P1L1 14 WKS 9.2 GMS 14HRS    9.2 GMS 
10 ANGALESHWARI 28 002865 IV G2P1L1 14 WKS 8.8 GMS 18HRS 30 MIN   8.8 GMS 
11 VELLAIYAMMAL  30 003008 IV G4P3L3 14 WKS 9.2 GMS 8 HRS30 MIN   9.2 GMS 
12 PONIRUL 24 033133 V G3P2L2 20 WKS 9.2 GMS FAILED INDUCTION   9.2 GMS 
13 RAJALAKSHMI 21 003138 IV G3P2L2 16 WKS 9 GMS 22 HRS 30 MIN FEVER 9 GMS 
14 NANSARA PARVEEN 19 035823 IV PRIMI 13 WKS 9 GMS 13 HRS30 MIN   9 GMS 
15 SHANTHI 22 037128 IV G2P1L1 16 WKS 9.8 GMS 15HRS    9.8 GMS 
16 VELLAIYAMMAL  31 003000 V G4P3L3 13 WKS - 14 HRS 30 MIN   - 
17 MAHESHWARI  28 003542 V G3P2L2 19 WKS 8.8 GMS FAILED INDUCTION FEVER 8.4GMS 
18 SUDHA 24 038428 IV G2P1L1 16 WKS 9.4 GMS 18 HRS30 MIN   9.4 GMS 
19 NAGALAKSHMI 23 041353 IV G3P2L2 16 WKS 9.2 GMS FAILED INDUCTION  DIARREA 9.2 GMS 
20 REVATHY 26 004151 V G4P3L3 14 WKS 9 GMS 7 HRS 45MIN   9 GMS 
21 POTHUMPONNU 22 036877 IV G3P2L2 13 WKS 9 GMS 22HRS    9 GMS 
22 SHANTHI  20 004366 IV G3P2L2 13 WKS 10 GMS 9 HRS   10 GMS 
23 JEYAPANDIAMMAL  28 004484 V G3P2L2 14 WKS 9 GMS 8 HRS    9 GMS 
24 SAHILA BANU 28 004795 IV PRIMI  14 WKS  9 GMS 20 HRS VOMITING 9 GMS 
25 NITHYA 27 004645 V G3P2L2  13 WKS  8.6 GMS 9 HRS 30 MIN   8.6 GMS 
26 KASIPRIYA 20 050772 V PRIMI  20  WKS  9.4 GMS 9 HRS45 MIN   9.2 GMS 
 
 
27 RAJAMANI 21 051441 IV PRIMI 20 WKS 9.8 GMS 14HRS15 MIN   9.8 GMS 
28 CHINNAPAPU 35 052953 V G2P1L1 14 WKS 9.8 GMS 10 HRS20 MIN   9.8 GMS 
29 MUTHUMARY 20 005384 IV G2P1L1 20 WKS 8.8 GMS 13 HRS   8.8 GMS 
30 MALAR 23 054870 V G3P2L2 20 WKS 10 GMS 10HRS15 MIN   9.6 GMS 
31 SUMATHY RANI 26 005426 IV PRIMI  19 WKS 8.6 GMS 22 HRS 30 MIN DIARREA 8.6 GMS 
32 BACKIYAM 23 005321 V G3P2L2 
15-16 
WKS  
8.4 GMS 21 HRS15  MIN    GMS 
33 VASANTHI 28 055127 IV G2P1L1 20 WKS 9.2 GMS 17 HRS 30 MIN   9 GMS 
34 BASARIYA BEGAM 22 005685 V G2P1P1 16 WKS 8.8 GMS 21 HRS 20 MIN FEVER 8.8 GMS 
35 MASILAKSHMI 21 060408 IV PRIMI 20 WKS 9 GMS 14 HRS    9 GMS 
36 JEYARANI 32 006047 V G3P2L2 20WKS 9.4 GMS 19 HRS30 MIN   9.4 GMS 
37 MATHI 25 006248 IV G4P3L3 14 WKS  8.8 GMS 5 HRS 10 MIN   8.8 GMS 
38 PANDIAMMAL 29 063055 V PRIMI 14 WKS 10 GMS 9 HRS 15 MIN   9.6 GMS 
39 KALA 26 006682 IV G3P2L2 16 WKS 9.2 GMS FAILED INDUCTION      9.2 GMS 
40 ALAGURANI 26 007961 V G2P1L1 16 WKS 10.2 GMS FAILED INDUCTION     10.2 GMS 
41 KAVITHA 30 069826 V G4P2A1 14 WKS  9 GMS 12 HRS   9 GMS 
42 LAKSHMI 30 008439 IV G2P1L1 20 WKS 9.4 GMS 18 HRS 30 MIN   9.4 GMS 
43 PANCHAVARNAM 23 008925 IV G3P2L2 13 WKS 9.8 GMS 14 HRS45 MIN   9.8 GMS 
44 MEENAKSHI 35 008098 V G3P2L2 16 WKS 9 GMS 15 HRS   9 GMS 
45 MUTHULAKSHMI 25 009638 IV G4P3L3 20 WKS 9 GMS 10 HRS 30 MIN   9 GMS 
46 VASUKI 28 009577 V G3P2L2 18 WKS 8.8 GMS 17 HRS    8.8 GMS 
47 CHITHAYI 26 008210 V G3P2L2 14 WKS 8.8 GMS 19HRS45 MIN DIARREA 8.6 GMS 
48 KAMATCHI 24 008879 IV G3P2L2 13 WKS 9.2 GMS 18 HRS   9.2 GMS 
49 THOTTESHWARI 28 009383 V G3P2L2 16 WKS 8.8 GMS 13 HRS15 MIN   8.8 GMS 
50 NADHIYA 19 007892 IV PRIMI  20 WKS 9 GMS 22 HRS   9 GMS 
 
